ReviewNeurosurgery practice2025
Impact of Revascularization Timing on Clinical Outcomes of Symptomatic Moyamoya Disease: A Systematic Review and Multivariate Analysis.
Review in Neurosurgery practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDespite a substantial body of literature describing the efficacy of revascularization compared with conventional management of moyamoya disease (MMD), the impact of the timing of revascularization relative to stroke onset remains inadequately characterized. The aim of this review was to synthesize existing research to guide clinicians in the optimal timing of revascularization in symptomatic MMD.
methodsA comprehensive literature review was performed to identify studies reporting on timing of revascularization. Studies were divided into revascularization within 3 months of stroke, between 3 and 6 months of stroke, or >6 months from stroke event.
resultsA total of 3049 cases and 3151 treated cerebral hemispheres were included. There were 91 individuals (2.98%) in the 3 months to intervention cohort, 152 (4.92%) individuals in the 3 to 6 months to the intervention cohort, and 2806 (92.0%) individuals in the >6 months to the intervention cohort. The average follow-up time was 43.8 ± 35.19 months. Clinical improvement was reported in 83.4% of cases overall. The 3-to-6-month poststroke preoperative interval has the highest frequency of clinical improvement (90.2%), followed by the >6-month preoperative interval (83.4%). The preoperative interval of <3 months had the lowest frequency of clinical improvement (76.5%). Comparison of average treatment effect in the treated demonstrated reduced frequency of improved clinical outcome (Mean difference: -22.6, SE: 9.15,
conclusionThe findings of this meta-analysis suggest that, in cases where it is clinically feasible to delay revascularization following an acute neurological event in patients with MMD, postponing intervention is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.